Vascular Biogenics, a biotech developing gene therapies for certain cancers and inflammatory diseases, announced terms for its IPO on Wednesday. The Or Yehuda, Israel-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $282 million.
Vascular Biogenics, which was founded in 2000, plans to list on the NASDAQ under the symbol VBLX. Deutsche Bank and Wells Fargo Securities are the joint bookrunners on the deal. It is expected to price during the week of July 28, 2014.
